AXIM Biotechnologies, Inc. Logo

AXIM Biotechnologies, Inc.

AXIM

(1.8)
Stock Price

0,00 USD

-1249.75% ROA

54.15% ROE

-0.28x PER

Market Cap.

1.207.836,00 USD

-66.23% DER

0% Yield

-4452.06% NPM

AXIM Biotechnologies, Inc. Stock Analysis

AXIM Biotechnologies, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

AXIM Biotechnologies, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (163.98%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0.4x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-59%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

5 ROA

The stock's ROA (-2267.34%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

AXIM Biotechnologies, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

AXIM Biotechnologies, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

AXIM Biotechnologies, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

AXIM Biotechnologies, Inc. Revenue
Year Revenue Growth
2011 10.000
2012 43.333 76.92%
2013 21.667 -100%
2014 0 0%
2015 49.139 100%
2016 47.059 -4.42%
2017 47.573 1.08%
2018 195.614 75.68%
2019 799.483 75.53%
2020 0 0%
2021 60.460 100%
2022 8.875 -581.24%
2023 38.324 76.84%
2023 39.518 3.02%
2024 69.916 43.48%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

AXIM Biotechnologies, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 571.455 100%
2016 235.579 -142.57%
2017 1.352.969 82.59%
2018 2.056.175 34.2%
2019 2.452.506 16.16%
2020 426.708 -474.75%
2021 284.869 -49.79%
2022 153.697 -85.34%
2023 138.852 -10.69%
2023 125.496 -10.64%
2024 16.252 -672.19%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

AXIM Biotechnologies, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 0
2012 38.387 100%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

AXIM Biotechnologies, Inc. EBITDA
Year EBITDA Growth
2011 -1.962
2012 -9.432 79.2%
2013 -79.219 88.09%
2014 -505.729 84.34%
2015 -10.048.426 94.97%
2016 -3.756.106 -167.52%
2017 -3.144.134 -19.46%
2018 -5.023.312 37.41%
2019 -6.499.157 22.71%
2020 -4.816.423 -34.94%
2021 -5.869.318 17.94%
2022 -4.226.389 -38.87%
2023 -1.927.120 -119.31%
2023 -2.323.820 17.07%
2024 -1.845.240 -25.94%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

AXIM Biotechnologies, Inc. Gross Profit
Year Gross Profit Growth
2011 10.000
2012 43.333 76.92%
2013 21.667 -100%
2014 0 0%
2015 -1.248 100%
2016 -107.071 98.83%
2017 4.716 2370.38%
2018 187.103 97.48%
2019 223.789 16.39%
2020 -16.001 1498.59%
2021 60.460 126.47%
2022 -417.251 114.49%
2023 38.324 1188.75%
2023 -387.501 109.89%
2024 -369.576 -4.85%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

AXIM Biotechnologies, Inc. Net Profit
Year Net Profit Growth
2011 -2.794
2012 -14.904 81.25%
2013 -89.219 83.3%
2014 -582.947 84.7%
2015 -10.092.766 94.22%
2016 -5.809.906 -73.72%
2017 -4.168.203 -39.39%
2018 -6.754.646 38.29%
2019 -6.771.465 0.25%
2020 -6.730.693 -0.61%
2021 -16.518.130 59.25%
2022 -5.956.966 -177.29%
2023 1.313.880 553.39%
2023 -8.059.682 116.3%
2024 -9.079.260 11.23%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

AXIM Biotechnologies, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

AXIM Biotechnologies, Inc. Free Cashflow
Year Free Cashflow Growth
2011 4.038
2012 -78.895 105.12%
2013 -33.018 -138.95%
2014 -338.999 90.26%
2015 -1.555.958 78.21%
2016 -1.294.141 -20.23%
2017 -3.081.956 58.01%
2018 -4.845.269 36.39%
2019 -5.020.142 3.48%
2020 -3.313.023 -51.53%
2021 -2.537.260 -30.57%
2022 -2.053.036 -23.59%
2023 -1.030.500 -99.23%
2023 -264.503 -289.6%
2024 -261.542 -1.13%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

AXIM Biotechnologies, Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 4.038
2012 21.105 80.87%
2013 -33.018 163.92%
2014 -338.999 90.26%
2015 -1.539.178 77.98%
2016 -1.294.141 -18.93%
2017 -3.081.956 58.01%
2018 -4.845.269 36.39%
2019 -5.020.142 3.48%
2020 -3.215.699 -56.11%
2021 -2.486.765 -29.31%
2022 -2.044.326 -21.64%
2023 -1.030.500 -98.38%
2023 -264.503 -289.6%
2024 -261.542 -1.13%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

AXIM Biotechnologies, Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 0
2012 100.000 100%
2013 0 0%
2014 0 0%
2015 16.780 100%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 97.324 100%
2021 50.495 -92.74%
2022 8.710 -479.74%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

AXIM Biotechnologies, Inc. Equity
Year Equity Growth
2010 100
2011 10.206 99.02%
2012 -4.698 317.24%
2013 -93.917 95%
2014 -580.723 83.83%
2015 -1.695.202 65.74%
2016 -2.371.590 28.52%
2017 -6.284.493 62.26%
2018 -6.081.819 -3.33%
2019 -6.760.397 10.04%
2020 1.565.821 531.75%
2021 -2.338.200 166.97%
2022 -4.825.412 51.54%
2023 -7.632.172 36.78%
2023 -5.955.066 -28.16%
2024 -9.533.790 37.54%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

AXIM Biotechnologies, Inc. Assets
Year Assets Growth
2010 0
2011 72.306 100%
2012 132.824 45.56%
2013 56.823 -133.75%
2014 738.457 92.31%
2015 1.261.609 41.47%
2016 1.449.172 12.94%
2017 2.192.150 33.89%
2018 2.089.254 -4.93%
2019 1.691.899 -23.49%
2020 11.314.395 85.05%
2021 5.323.435 -112.54%
2022 4.212.035 -26.39%
2023 4.146.022 -1.59%
2023 4.043.956 -2.52%
2024 3.728.695 -8.45%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

AXIM Biotechnologies, Inc. Liabilities
Year Liabilities Growth
2010 0
2011 62.100 100%
2012 137.522 54.84%
2013 150.740 8.77%
2014 1.319.180 88.57%
2015 2.956.811 55.39%
2016 3.820.762 22.61%
2017 8.476.643 54.93%
2018 8.171.073 -3.74%
2019 8.452.296 3.33%
2020 9.748.574 13.3%
2021 7.661.635 -27.24%
2022 9.037.447 15.22%
2023 11.778.195 23.27%
2023 9.999.022 -17.79%
2024 13.262.485 24.61%

AXIM Biotechnologies, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.01
Price to Earning Ratio
-0.28x
Price To Sales Ratio
13x
POCF Ratio
-0.73
PFCF Ratio
-0.77
Price to Book Ratio
-0.12
EV to Sales
81.92
EV Over EBITDA
-4.03
EV to Operating CashFlow
-4.84
EV to FreeCashFlow
-4.83
Earnings Yield
-3.58
FreeCashFlow Yield
-1.31
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.1
Graham NetNet
-0.05

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
0.38
ROE
0.54
Return On Assets
-1.11
Return On Capital Employed
0.81
Net Income per EBT
1
EBT Per Ebit
1.79
Ebit per Revenue
-24.93
Effective Tax Rate
0.07

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.98
Stock Based Compensation to Revenue
0.99
Gross Profit Margin
-2.48
Operating Profit Margin
-24.93
Pretax Profit Margin
-44.52
Net Profit Margin
-44.52

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
-0
Capex to Revenue
0.03
Capex to Depreciation
0.01
Return on Invested Capital
0.67
Return on Tangible Assets
-12.5
Days Sales Outstanding
-55.79
Days Payables Outstanding
1416.34
Days of Inventory on Hand
12.01
Receivables Turnover
-6.54
Payables Turnover
0.26
Inventory Turnover
30.38
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,03
Tangible Book Value per Share
-0.04
Shareholders Equity per Share
-0.03
Interest Debt per Share
0.02
Debt to Equity
-0.66
Debt to Assets
1.69
Net Debt to EBITDA
-3.39
Current Ratio
0
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-2853690
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0.91
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
7099.5
Debt to Market Cap
5.23

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

AXIM Biotechnologies, Inc. Dividends
Year Dividends Growth

AXIM Biotechnologies, Inc. Profile

About AXIM Biotechnologies, Inc.

AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker for dry eye disease; SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.

CEO
Ms. Catalina Valencia J.D.
Employee
6
Address
6191 Cornerstone Court, East
San Diego, 92121

AXIM Biotechnologies, Inc. Executives & BODs

AXIM Biotechnologies, Inc. Executives & BODs
# Name Age
1 Mr. Jeffrey A. Busby
Senior Vice President of Business Development
70
2 Dr. Sergei A. Svarovsky M.B.A., Ph.D.
Chief Scientific Officer & Co-Founder of Sapphire Biotech, Inc.
70
3 Dr. Douglas Lake Ph.D.
Chief Clinical Officer of Sapphire Biotech, Inc.
70
4 Ms. Catalina Valencia J.D.
President & Director
70
5 Mr. Robert T. Malasek
Chief Financial Officer & Secretary
70
6 Mr. Kurt Phinney
Chief Operating Officer
70
7 Dr. Maria J. Gonzalez Moa Ph.D.
Vice President of Product Development - Sapphire Biotech, Inc.
70
8 Dr. Alim Seit-Nebi Ph.D.
Chief Technology Officer & Co-Founder of Sapphire Biotech, Inc.
70
9 Dr. Joseph Tauber M.D.
Chief Medical Officer & Chairman of the Medical Advisory Board
70

AXIM Biotechnologies, Inc. Competitors